中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
11期
1642-1644,后插2
,共4页
吴东平%赵建国%叶万立%王晓燕
吳東平%趙建國%葉萬立%王曉燕
오동평%조건국%협만립%왕효연
食管肿瘤%癌,鳞状细胞%化学疗法%紫杉醇%顺铂
食管腫瘤%癌,鱗狀細胞%化學療法%紫杉醇%順鉑
식관종류%암,린상세포%화학요법%자삼순%순박
Esophageal neoplasms%Carcinoma,squamous cell%Chemotherapy%Paclitaxel%Cisplatin
目的 观察紫杉醇联合顺铂治疗晚期食管鳞癌的疗效及不良反应.方法 用紫杉醇注射液175mg/m2静脉滴注3h,第1天；顺铂25mg/m2,静脉滴注,第1-3天.该方案治疗25例晚期食管鳞癌,3周为1个周期.结果 25例患者共完成化疗周期数为104个,其中完全缓解1例(4.1％),部分缓解10例(41.7％),稳定9例(37.5％),进展4例(16.7％),总有效率为45.8％(11/24).至末次随访,死亡20例,全组中位生存期11.0个月(95％CI:8.35～13.65个月),1年生存率37.3％.12例治疗有效病例的中位生存期为12.5个月(95％CI:9.11～ 15.90个月),治疗无效病例的中位生存期为8.0个月(95％CI:5.50～9.50个月),获治疗有效病例的中位生存期显著好于无效病例(P =0.022).主要毒副反应有:白细胞减少(Ⅲ度7例,Ⅳ度1例)、中性粒细胞减少(Ⅲ度5例,Ⅳ度1例)、血小板下降(Ⅲ度1例)和脱发(Ⅱ度19例).结论 紫杉醇联合顺铂方案治疗晚期食管癌有效安全,可作为晚期食管鳞癌首选化疗方案.
目的 觀察紫杉醇聯閤順鉑治療晚期食管鱗癌的療效及不良反應.方法 用紫杉醇註射液175mg/m2靜脈滴註3h,第1天；順鉑25mg/m2,靜脈滴註,第1-3天.該方案治療25例晚期食管鱗癌,3週為1箇週期.結果 25例患者共完成化療週期數為104箇,其中完全緩解1例(4.1％),部分緩解10例(41.7％),穩定9例(37.5％),進展4例(16.7％),總有效率為45.8％(11/24).至末次隨訪,死亡20例,全組中位生存期11.0箇月(95％CI:8.35～13.65箇月),1年生存率37.3％.12例治療有效病例的中位生存期為12.5箇月(95％CI:9.11～ 15.90箇月),治療無效病例的中位生存期為8.0箇月(95％CI:5.50～9.50箇月),穫治療有效病例的中位生存期顯著好于無效病例(P =0.022).主要毒副反應有:白細胞減少(Ⅲ度7例,Ⅳ度1例)、中性粒細胞減少(Ⅲ度5例,Ⅳ度1例)、血小闆下降(Ⅲ度1例)和脫髮(Ⅱ度19例).結論 紫杉醇聯閤順鉑方案治療晚期食管癌有效安全,可作為晚期食管鱗癌首選化療方案.
목적 관찰자삼순연합순박치료만기식관린암적료효급불량반응.방법 용자삼순주사액175mg/m2정맥적주3h,제1천；순박25mg/m2,정맥적주,제1-3천.해방안치료25례만기식관린암,3주위1개주기.결과 25례환자공완성화료주기수위104개,기중완전완해1례(4.1％),부분완해10례(41.7％),은정9례(37.5％),진전4례(16.7％),총유효솔위45.8％(11/24).지말차수방,사망20례,전조중위생존기11.0개월(95％CI:8.35～13.65개월),1년생존솔37.3％.12례치료유효병례적중위생존기위12.5개월(95％CI:9.11～ 15.90개월),치료무효병례적중위생존기위8.0개월(95％CI:5.50～9.50개월),획치료유효병례적중위생존기현저호우무효병례(P =0.022).주요독부반응유:백세포감소(Ⅲ도7례,Ⅳ도1례)、중성립세포감소(Ⅲ도5례,Ⅳ도1례)、혈소판하강(Ⅲ도1례)화탈발(Ⅱ도19례).결론 자삼순연합순박방안치료만기식관암유효안전,가작위만기식관린암수선화료방안.
Objective To evaluate the efficacy and safety of paclitaxel plus cisplatin combination in treatment patients with advanced or metastatic squamous-cell carcinoma of the esophagus(ESCC).Methods Twenty-five patients with advanced or metastatic ESCC received paclitaxel 175mg/m2 by 3-hour infusion on day 1 and cisplatin 25mg/m2 by infusion on day 1 ～ 3.3 weeks as one cycle.Results Twenty-four patients were eligible to be evaluated the efficacy and safety.The overall response rate was 45.8％ with complete and partial response rates of 4.1％ and 41.7％,respectively.The median survival time of all patients was 11 months(95％ CI:8.35 ～ 13.65 months).There was significant difference in the median overall survival between the patients who had showed response versus those who had not(P =0.022).Median survival was 12.5 months(95％ CI:9.11 ～ 15.90 months) and 8 months(95％CI:5.50 -9.50 months),respectively.The 1-year survival probability was 37.3％.The most common toxicities were leukopenia,neutropenia,thrombocytopenia and alopecia.Conclusion The effect of paclitaxel and cisplatin which seems beneficial as first-line therapy in advanced squamous-cell carcinoma of the esophagus had a high effective rate with acceptable toxicity.
